The metabolic reprogramming of breast epithelial cells caused by these changes contributes to the suppression of tumor progression, suggesting that the tumor-delaying effect of FGFR4 deficiency may be largely attributed to the elevated anti-obesogenic FGF21 and its resultant metabolic effects 190. The gene discussed is FGF21; the disease is neoplasm.